Anti-acid Therapies in Idiopathic Pulmonary Fibrosis: Premature to Dismiss?
- PMID: 35921176
- PMCID: PMC9746836
- DOI: 10.1164/rccm.202207-1420LE
Anti-acid Therapies in Idiopathic Pulmonary Fibrosis: Premature to Dismiss?
Comment in
-
Reply to Cottin et al., to Johannson et al., to Scholand and Wells, and to Crowley et al.Am J Respir Crit Care Med. 2023 Jun 1;207(11):1542-1543. doi: 10.1164/rccm.202305-0786LE. Am J Respir Crit Care Med. 2023. PMID: 37130124 Free PMC article. No abstract available.
Comment on
-
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST. Am J Respir Crit Care Med. 2022. PMID: 35486072 Free PMC article.
Similar articles
-
Reply to Kobayashi et al.: Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis.Am J Respir Crit Care Med. 2020 Jun 1;201(11):1450-1451. doi: 10.1164/rccm.202002-0398LE. Am J Respir Crit Care Med. 2020. PMID: 32150449 Free PMC article. No abstract available.
-
Idiopathic pulmonary fibrosis or not: antibiotic prophylaxis for all patients on immunosuppressants.Thorax. 2013 Sep;68(9):883-4. doi: 10.1136/thoraxjnl-2013-203395. Epub 2013 Apr 5. Thorax. 2013. PMID: 23564341 No abstract available.
-
Rethinking treatment strategies for idiopathic pulmonary fibrosis: Reevaluation of anti-inflammatory and immunosuppressive therapies.Respir Investig. 2023 Jan;61(1):58-60. doi: 10.1016/j.resinv.2022.10.007. Epub 2022 Nov 30. Respir Investig. 2023. PMID: 36460586 No abstract available.
-
Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications.Expert Rev Respir Med. 2016 Jun;10(6):699-711. doi: 10.1080/17476348.2016.1177461. Epub 2016 Apr 26. Expert Rev Respir Med. 2016. PMID: 27094006 Review.
-
Is pirfenidone effective for idiopathic pulmonary fibrosis?Medwave. 2017 Jan 17;17(Suppl1):e6843. doi: 10.5867/medwave.2017.6844. Medwave. 2017. PMID: 28112713 Review. English, Spanish.
Cited by
-
The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): study protocol for a randomised placebo-controlled multicentre clinical trial.BMJ Open. 2025 Feb 5;15(2):e088604. doi: 10.1136/bmjopen-2024-088604. BMJ Open. 2025. PMID: 39909521 Free PMC article.
-
Reply to Cottin et al., to Johannson et al., to Scholand and Wells, and to Crowley et al.Am J Respir Crit Care Med. 2023 Jun 1;207(11):1542-1543. doi: 10.1164/rccm.202305-0786LE. Am J Respir Crit Care Med. 2023. PMID: 37130124 Free PMC article. No abstract available.
References
-
- Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med . 2015;192:e3–e19. - PubMed
-
- TIPAL - Treating People with Idiopathic Pulmonary Fibrosis with the Addition of Lansoprazole [Internet] 2022. https://www.uea.ac.uk/web/groups-and-centres/projects/tipal
-
- Khor YH, Bissell B, Ghazipura M, Herman D, Hon SM, Hossain T, et al. Antacid medication and antireflux surgery in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc . 2022;19:833–844. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources